Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Gastric Cancer

  Free Subscription


Articles published in Eur J Cancer

Retrieve available abstracts of 36 articles:
HTML format
Text format



Single Articles


    March 2018
  1. HEWITT LC, Inam IZ, Saito Y, Yoshikawa T, et al
    Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.
    Eur J Cancer. 2018;94:104-114.
    PubMed     Text format     Abstract available


  2. ROVIELLO F, Polom K, D'Ignazio A, Pascale V, et al
    Potential impact of molecular classification on tailored lymphadenectomy for gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S8.
    PubMed     Text format    


  3. CHIAPPA A, Bertani E, Fazio N, Foschi D, et al
    D2-lymphadenectomy and gastric resection in a consecutive series of patients with gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S7.
    PubMed     Text format    


  4. BENCIVENGA M, Treppiedi E, Verlato G, Mengardo V, et al
    The amount of cells with Signet Ring Cell morphology has a prognostic impact in poorly cohesive gastric carcinoma.
    Eur J Cancer. 2018;92 Suppl 2:S6.
    PubMed     Text format    


  5. ROVIELLO F, Polom K, D'Ignazio A, Pascale V, et al
    K-RAS mutation in gastric cancer and its link with microsatellite instability status.
    Eur J Cancer. 2018;92 Suppl 2:S6.
    PubMed     Text format    


  6. CARNEIRO F
    Hereditary gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S4.
    PubMed     Text format    


  7. ROVIELLO F
    The role of HIPEC in gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S4-S5.
    PubMed     Text format    


  8. TERASHIMA M
    Perioperative treatment strategies and current studies to improve gastric cancer outcomes in Japan.
    Eur J Cancer. 2018;92 Suppl 2:S3.
    PubMed     Text format    


  9. LORDICK F
    Response-adapted treatment stratification in oesophago-gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S3.
    PubMed     Text format    


  10. LAURENT-PUIG P
    Oesophago-gastric cancer: One disease or separate entities?: Translating molecular subtyping into clinical practice.
    Eur J Cancer. 2018;92 Suppl 2:S1.
    PubMed     Text format    


    January 2018
  11. BANDO H, Shimodaira H, Fujitani K, Takashima A, et al
    A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Eur J Cancer. 2018;91:86-91.
    PubMed     Text format     Abstract available


    December 2017
  12. WANG H, Li B, Liu Z, Gong J, et al
    HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
    Eur J Cancer. 2017;88:92-100.
    PubMed     Text format     Abstract available


    August 2017
  13. COURTOIS S, Duran RV, Giraud J, Sifre E, et al
    Metformin targets gastric cancer stem cells.
    Eur J Cancer. 2017;84:193-201.
    PubMed     Text format     Abstract available


  14. STAHL M, Walz MK, Riera-Knorrenschild J, Stuschke M, et al
    Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial.
    Eur J Cancer. 2017;81:183-190.
    PubMed     Text format     Abstract available


  15. KWAKMAN JJM, Baars A, van Zweeden AA, de Mol P, et al
    Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
    Eur J Cancer. 2017;81:130-134.
    PubMed     Text format    


    July 2017
  16. PARK SR, Kim MJ, Nam BH, Kim CG, et al
    A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer.
    Eur J Cancer. 2017;83:32-42.
    PubMed     Text format     Abstract available


  17. KEMPF E, Tournigand C, Rochigneux P, Aubry R, et al
    Discrepancies in the use of chemotherapy and artificial nutrition near the end of life for hospitalised patients with metastatic gastric or oesophageal cancer. A countrywide, register-based study.
    Eur J Cancer. 2017;79:31-40.
    PubMed     Text format     Abstract available


  18. PERNOT S, Badoual C, Terme M, Castan F, et al
    Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.
    Eur J Cancer. 2017;79:15-22.
    PubMed     Text format     Abstract available


    June 2017
  19. D'AMBROSIO L, Palesandro E, Boccone P, Tolomeo F, et al
    Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.
    Eur J Cancer. 2017;78:122-132.
    PubMed     Text format     Abstract available


  20. HAJ MOHAMMAD N, Bernards N, van Putten M, Lemmens VEPP, et al
    Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer.
    Eur J Cancer. 2017;78:28-36.
    PubMed     Text format     Abstract available


    May 2017
  21. FARAG S, Somaiah N, Choi H, Heeres B, et al
    Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Eur J Cancer. 2017;76:76-83.
    PubMed     Text format     Abstract available


  22. PETRELLI F, Tomasello G, Barni S
    Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
    Eur J Cancer. 2017;76:8-16.
    PubMed     Text format     Abstract available


    April 2017
  23. DESIDERIO J, Chao J, Melstrom L, Warner S, et al
    The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer.
    Eur J Cancer. 2017;79:1-14.
    PubMed     Text format     Abstract available


    February 2017
  24. IENI A, Angelico G, Zeppa P, Tuccari G, et al
    Letter to the Editor regarding the paper by Park et al., Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER
    Eur J Cancer. 2017;75:190-191.
    PubMed     Text format    


    December 2016
  25. OH HJ, Lim CH, Yoon BH, Yoon SB, et al
    Fracture after gastrectomy for gastric cancer: A long-term follow-up observational study.
    Eur J Cancer. 2016;72:28-36.
    PubMed     Text format     Abstract available


    August 2016
  26. YOSHINO S, Nishikawa K, Morita S, Takahashi T, et al
    Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701).
    Eur J Cancer. 2016;65:164-171.
    PubMed     Text format     Abstract available


    July 2016
  27. TSAI MM, Wang CS, Tsai CY, Huang CG, et al
    Circulating microRNA-196a/b are novel biomarkers associated with metastatic gastric cancer.
    Eur J Cancer. 2016;64:137-148.
    PubMed     Text format     Abstract available


    May 2016
  28. YOSHIKAWA T, Morita S, Tanabe K, Nishikawa K, et al
    Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric
    Eur J Cancer. 2016;62:103-111.
    PubMed     Text format     Abstract available


  29. BANDO H, Doi T, Muro K, Yasui H, et al
    A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
    Eur J Cancer. 2016;62:46-53.
    PubMed     Text format     Abstract available


    April 2016
  30. MONTALVO-JAVE EE, Olguin-Martinez M, Hernandez-Espinosa DR, Sanchez-Sevilla L, et al
    Role of NADPH oxidases in inducing a selective increase of oxidant stress and cyclin D1 and checkpoint 1 over-expression during progression to human gastric adenocarcinoma.
    Eur J Cancer. 2016;57:50-7.
    PubMed     Text format     Abstract available


    December 2015
  31. PARK SR, Park YS, Ryu MH, Ryoo BY, et al
    Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1).
    Eur J Cancer. 2015;53:42-50.
    PubMed     Text format     Abstract available


  32. LEE HH, Park JM, Song KY, Choi MG, et al
    Survival impact of postoperative body mass index in gastric cancer patients undergoing gastrectomy.
    Eur J Cancer. 2015;52:129-137.
    PubMed     Text format     Abstract available


    November 2015
  33. FANG X, Wei J, He X, An P, et al
    Landscape of dietary factors associated with risk of gastric cancer: A systematic review and dose-response meta-analysis of prospective cohort studies.
    Eur J Cancer. 2015 Nov 14. pii: S0959-8049(15)00856.
    PubMed     Text format     Abstract available


    September 2015
  34. SYLVIE L, Silvia S, Salah-Eddin AB, Markus F, et al
    Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer.
    Eur J Cancer. 2015;51:1918-26.
    PubMed     Text format     Abstract available


    June 2015
  35. ARNOLD M, Karim-Kos HE, Coebergh JW, Byrnes G, et al
    Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory.
    Eur J Cancer. 2015;51:1164-87.
    PubMed     Text format     Abstract available


    March 2015
  36. LORENZEN S, Riera Knorrenschild J, Haag GM, Pohl M, et al
    Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Eur J Cancer. 2015;51:569-76.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gastric Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: